Collaboration will leverage HUYA’s growing Chinese bioscience network
San Diego, CA – April 21, 2009 — HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.
Abbott will gain access to HUYA’s growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. HUYA has agreements in place with many of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug candidates. Continue reading